PLERIXAFOR TEVA 20 mg/ml, solution for injection bottle, 1.2 ml
Active ingredients: PLÉRIXAFOR
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 1.2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PLERIXAFOR TEVA 20 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 1,2 mL
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 25 Feb 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65998504CIP73027128CIP133400930271285Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PLÉRIXAFORsolution | 20 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: PLERIXAFOR 20 mg/ml - MOZOBIL 20 mg/ml, solution pour injection